Lena K Tholfsen1, Jan P Larsen1, Jörn Schulz1, Ole-Bjorn Tysnes1, Michaela D Gjerstad2. 1. From The Norwegian Centre for Movement Disorders (L.K.T., J.P.L., J.S., M.D.G.), Stavanger; Department of Neurology (L.K.T., M.D.G.), Stavanger University Hospital; and Department of Neurology (O-B.T.), Haukeland University Hospital, Bergen, Norway. 2. From The Norwegian Centre for Movement Disorders (L.K.T., J.P.L., J.S., M.D.G.), Stavanger; Department of Neurology (L.K.T., M.D.G.), Stavanger University Hospital; and Department of Neurology (O-B.T.), Haukeland University Hospital, Bergen, Norway. gjmi@sus.no.
Abstract
OBJECTIVE: To examine the frequency, development, and risk factors of excessive daytime sleepiness (EDS) in a cohort of originally drug-naive patients with incident Parkinson disease (PD) during the first 5 years after diagnosis. METHODS: One hundred fifty-three drug-naive patients with early PD derived from a population-based incident cohort and 169 control participants were assessed for EDS and reevaluated after 1, 3, and 5 years on medication. EDS was diagnosed according to the Epworth Sleepiness Scale. Cutoff score above 10 was applied. Generalized estimating equation models for correlated data were used to examine associated and risk factors for EDS. RESULTS: Patients reported EDS more often than control participants at the time of diagnosis and during follow-up. The frequency of EDS in PD increased from 11.8% at baseline to 23.4% after 5 years. Associated factors were male sex, the use of dopamine agonists, and higher Montgomery-Åsberg Depression Rating Scale and Unified Parkinson's Disease Rating Scale-activities of daily living scores. Main risk factor for developing EDS was an increased Epworth Sleepiness Scale score at baseline. CONCLUSION: EDS is more frequent in PD even before treatment initiation compared with control participants and increases in occurrence with disease progression. The main risk factor for developing EDS with time is an early predisposition for sleepiness. In addition, the use of dopamine agonists was associated with the development of EDS. These findings necessitate caution in patients with PD and early increased sleep propensity and when using dopamine agonists.
OBJECTIVE: To examine the frequency, development, and risk factors of excessive daytime sleepiness (EDS) in a cohort of originally drug-naive patients with incident Parkinson disease (PD) during the first 5 years after diagnosis. METHODS: One hundred fifty-three drug-naive patients with early PD derived from a population-based incident cohort and 169 control participants were assessed for EDS and reevaluated after 1, 3, and 5 years on medication. EDS was diagnosed according to the Epworth Sleepiness Scale. Cutoff score above 10 was applied. Generalized estimating equation models for correlated data were used to examine associated and risk factors for EDS. RESULTS:Patients reported EDS more often than control participants at the time of diagnosis and during follow-up. The frequency of EDS in PD increased from 11.8% at baseline to 23.4% after 5 years. Associated factors were male sex, the use of dopamine agonists, and higher Montgomery-Åsberg Depression Rating Scale and Unified Parkinson's Disease Rating Scale-activities of daily living scores. Main risk factor for developing EDS was an increased Epworth Sleepiness Scale score at baseline. CONCLUSION: EDS is more frequent in PD even before treatment initiation compared with control participants and increases in occurrence with disease progression. The main risk factor for developing EDS with time is an early predisposition for sleepiness. In addition, the use of dopamine agonists was associated with the development of EDS. These findings necessitate caution in patients with PD and early increased sleep propensity and when using dopamine agonists.
Authors: Yue Leng; Samuel M Goldman; Peggy M Cawthon; Katie L Stone; Sonia Ancoli-Israel; Kristine Yaffe Journal: Int J Epidemiol Date: 2018-10-01 Impact factor: 7.196
Authors: Amy W Amara; Lama M Chahine; Chelsea Caspell-Garcia; Jeffrey D Long; Christopher Coffey; Birgit Högl; Aleksandar Videnovic; Alex Iranzo; Geert Mayer; Nancy Foldvary-Schaefer; Ron Postuma; Wolfgang Oertel; Shirley Lasch; Ken Marek; Tanya Simuni Journal: J Neurol Neurosurg Psychiatry Date: 2017-05-29 Impact factor: 10.154
Authors: Adrianus L A J Hommel; Marjan J Meinders; Stefan Lorenzl; Richard Dodel; Miguel Coelho; Joaquim J Ferreira; Brice Laurens; Umberto Spampinato; Wassilios Meissner; Kristina Rosqvist; Jonathan Timpka; Per Odin; Michael Wittenberg; Bas R Bloem PhD; Raymond T Koopmans; Anette Schrag Journal: Mov Disord Clin Pract Date: 2020-05-21